Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial
Li, Jing-Xin, PhD, Hou, Li-Hua, PhD, Meng, Fan-Yue, MSc, Wu, Shi-Po, PhD, Hu, Yue-Mei, BS, Liang, Qi, BS, Chu, Kai, MSc, Zhang, Zhe, BS, Xu, Jun-Jie, PhD, Tang, Rong, MSc, Wang, Wen-Juan, MSc, Liu, Pei, Prof, Hu, Jia-Lei, MSc, Luo, Li, MSc, Jiang, Rong, MSc, Zhu, Feng-Cai, MSc, Chen, Wei, PhD
Published in The Lancet global health (01.03.2017)
Published in The Lancet global health (01.03.2017)
Get full text
Journal Article
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
Zhu, Feng-Cai, MSc, Hou, Li-Hua, PhD, Li, Jing-Xin, MSc, Wu, Shi-Po, PhD, Liu, Pei, Prof, Zhang, Gui-Rong, PhD, Hu, Yue-Mei, BSc, Meng, Fan-Yue, MSc, Xu, Jun-Jie, PhD, Tang, Rong, MSc, Zhang, Jin-Long, PhD, Wang, Wen-Juan, MSc, Duan, Lei, MSc, Chu, Kai, MSc, Liang, Qi, MSc, Hu, Jia-Lei, MSc, Luo, Li, MSc, Zhu, Tao, PhD, Wang, Jun-Zhi, PhD, Chen, Wei, Dr
Published in The Lancet (British edition) (06.06.2015)
Published in The Lancet (British edition) (06.06.2015)
Get full text
Journal Article